Multiple ischemic strokes associated with use of recombinant activated factor VII.

نویسندگان

  • Richard B Libman
  • Cordrin Lungu
  • Thomas Kwiatkowski
چکیده

BACKGROUND Intracerebral hemorrhage is associated with a high rate of mortality and functional disability. For most patients, no treatment other than supportive care has been shown to improve outcome. Preliminary studies suggest that recombinant activated factor VII may limit early hematoma growth and improve functional outcome. However, ischemic complications may occur in some patients. OBJECTIVE To report a case of severe cerebral ischemic complications associated with the use of recombinant activated factor VII. DESIGN Case report. SETTING Tertiary care medical center. PATIENT We describe a patient with ischemic stroke who developed hemorrhagic conversion following tissue plasminogen activator administration. INTERVENTIONS Treatment with recombinant activated factor VII, in addition to standard treatment with cryoprecipitate and platelets. MAIN OUTCOME MEASURE Brain imaging showing multiple ischemic strokes. RESULTS The patient subsequently developed multiple acute cerebral infarcts in different vascular distributions. CONCLUSION Although the exact relationship between treatment with recombinant activated factor VII and the development of multiple ischemic strokes remains uncertain, this case suggests that a cautious approach to treatment with this agent is warranted until more data are available.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Recombinant activated factor VII for acute intracerebral hemorrhage

Acute stroke is the third leading cause of death worldwide, exceeded only by coronary artery disease and cancer. There are two major subtypes of strokeischemic and hemorrhagic with 20-30% of all strokes being hemorrhagic in nature. The incidence of ischemic strokes has steadily declined by virtue of rigorous risk factor modification, but the same has not been possible for hemorrhagic strokes. M...

متن کامل

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)

Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...

متن کامل

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

متن کامل

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

متن کامل

Preparation of factor VII concentrate using CNBr-activated

  Background: Factor VII concentrates are used in patients with congenital or acquired factor VII deficiency or treatment of hemophilia patients with inhibitors. In this research, immunoaffinity chromatography was used to purify factor VII from prothrombin complex (Prothrombin-Proconvertin-Stuart Factor-Antihemophilic Factor B or PPSB) which contains coagulation factors II, VII, IX and X. The a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Archives of neurology

دوره 64 6  شماره 

صفحات  -

تاریخ انتشار 2007